{"filing":{"accession_number":"0001628280-26-042237","cik":"0001706431","ticker":"VIR","company_name":"Vir Biotechnology, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"vir-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026042237/vir-20260609.htm"},"events":[{"id":5783,"run_id":5070,"accession_number":"0001628280-26-042237","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on the Board's approval of Timothy Coughlin's appointment as a Class III director effective immediately, along with his appointment as Chair of the Audit Committee. While the filing also mentions standard non-employee director compensation arrangements, the principal disclosed action is the appointment of a new director and committee chair, making exec_appointment the most salient classification.","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5902,"accession_number":"0001628280-26-042237","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Board's approval of Timothy Coughlin's appointment as a Class III director effective immediately, along with his appointment as Chair of the Audit Committee. While the filing also mentions standard non-employee director compensation arrangements, the principal disclosed action is the appointment of a new director and committee chair, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:28:06.611292+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5902,"accession_number":"0001628280-26-042237","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the Board's approval of Timothy Coughlin's appointment as a Class III director effective immediately, along with his appointment as Chair of the Audit Committee. While the filing also mentions standard non-employee director compensation arrangements, the principal disclosed action is the appointment of a new director and committee chair, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:28:06.611292+00:00","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-06-10"}]}